Intranasal Immunization with Recombinant Vesicular Stomatitis Virus Expressing Murine Cytomegalovirus Glycoprotein B Induces Humoral and Cellular Immunity

Overview

Journal Comp Med

Specialty General Medicine

Date 2008 Jun 6

PMID 18524170

Citations 8

Authors

Steven R Wilson

Jean H Wilson

Linda Buonocore

Amy Palin

John K Rose

Jon D Reuter

Affiliations

Soon will be listed here.

Abstract

Cytomegalovirus is a leading cause of morbidity and mortality among neonatal and immunocompromised patients. The use of vaccine prophylaxis continues to be an effective approach to reducing viral infections and their associated diseases. Murine cytomegalovirus (mCMV) has proven to be a valuable animal model in determining the efficacy of newly developed vaccine strategies in vivo. Live recombinant vesicular stomatitis viruses (rVSV) have successfully been used as vaccine vectors for several viruses to induce strong humoral and cellular immunity. We tested the ability of intranasal immunization with an rVSV expressing the major envelope protein of mCMV, glycoprotein B (gB), to protect against challenge with mCMV in a mouse model. rVSV-gB-infected cells showed strong cytoplasmic and cell surface expression of gB, and neutralizing antibodies to gB were present in mice after a single intranasal vaccination of VSV-gB. After challenge with mCMV, recovery of live virus and viral DNA was significantly reduced in immunized mice. In addition, primed splenocytes produced a CD8+ IFNgamma response to gB. The ability to induce an immune response to a gene product through mucosal vaccination with rVSV-gB represents a potentially effective approach to limiting CMV-induced disease.

Citing Articles

Rhabdoviruses as vectors for vaccines and therapeutics.

Scher G, Schnell M Curr Opin Virol. 2020; 44:169-182.

PMID: 33130500 PMC: 8331071. DOI: 10.1016/j.coviro.2020.09.003.

A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

Diamond D, La Rosa C, Chiuppesi F, Contreras H, Dadwal S, Wussow F Expert Rev Vaccines. 2018; 17(10):889-911.

PMID: 30246580 PMC: 6343505. DOI: 10.1080/14760584.2018.1526085.

Vaccination against the human cytomegalovirus.

Plotkin S, Boppana S Vaccine. 2018; 37(50):7437-7442.

PMID: 29622379 PMC: 6892274. DOI: 10.1016/j.vaccine.2018.02.089.

Advancing Our Understanding of Protective Maternal Immunity as a Guide for Development of Vaccines To Reduce Congenital Cytomegalovirus Infections.

Permar S, Schleiss M, Plotkin S J Virol. 2018; 92(7).

PMID: 29343580 PMC: 5972872. DOI: 10.1128/JVI.00030-18.

Cytomegalovirus Vaccines: Current Status and Future Prospects.

Anderholm K, Bierle C, Schleiss M Drugs. 2016; 76(17):1625-1645.

PMID: 27882457 PMC: 5628252. DOI: 10.1007/s40265-016-0653-5.

References

Cheung K, Li J, Falletta J, Wagner J, Lang D . Murine cytomegalovirus infection: hematological, morphological, and functional study of lymphoid cells. Infect Immun. 1981; 33(1):239-49. PMC: 350682. DOI: 10.1128/iai.33.1.239-249.1981. View

Gonczol E, Furlini G, Ianacone J, Plotkin S . A rapid microneutralization assay for cytomegalovirus. J Virol Methods. 1986; 14(1):37-41. DOI: 10.1016/0166-0934(86)90005-4. View

Shanley J, Wu C . Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity. Vaccine. 2003; 21(19-20):2632-42. DOI: 10.1016/s0264-410x(03)00037-9. View

Britt W, Vugler L, Butfiloski E, Stephens E . Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol. 1990; 64(3):1079-85. PMC: 249220. DOI: 10.1128/JVI.64.3.1079-1085.1990. View

Schlereth B, Buonocore L, Tietz A, Meulen V, Rose J, Niewiesk S . Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol. 2003; 84(Pt 8):2145-2151. DOI: 10.1099/vir.0.19050-0. View

Britt W . Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus. Virology. 1984; 135(2):369-78. DOI: 10.1016/0042-6822(84)90193-4. View

Wiley C, Schrier R, Denaro F, Nelson J, LAMPERT P, Oldstone M . Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. J Neuropathol Exp Neurol. 1986; 45(2):127-39. DOI: 10.1097/00005072-198603000-00003. View

Spitzer P, Tarsy D, Eliopoulos G . Acute transverse myelitis during disseminated cytomegalovirus infection in a renal transplant recipient. Transplantation. 1987; 44(1):151-3. View

Schleiss M . Progress in cytomegalovirus vaccine development. Herpes. 2006; 12(3):66-75. View

10.

Roberts A, Kretzschmar E, Perkins A, Forman J, Price R, Buonocore L . Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol. 1998; 72(6):4704-11. PMC: 109996. DOI: 10.1128/JVI.72.6.4704-4711.1998. View

11.

Reddehase M, Podlech J, Grzimek N . Mouse models of cytomegalovirus latency: overview. J Clin Virol. 2002; 25 Suppl 2:S23-36. DOI: 10.1016/s1386-6532(02)00087-2. View

12.

Brave A, Ljungberg K, Wahren B, Liu M . Vaccine delivery methods using viral vectors. Mol Pharm. 2007; 4(1):18-32. DOI: 10.1021/mp060098+. View

13.

Reddehase M, Balthesen M, Rapp M, Jonjic S, Pavic I, Koszinowski U . The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med. 1994; 179(1):185-93. PMC: 2191331. DOI: 10.1084/jem.179.1.185. View

14.

Allan J, Shellam G . Genetic control of murine cytomegalovirus infection: virus titres in resistant and susceptible strains of mice. Arch Virol. 1984; 81(1-2):139-50. DOI: 10.1007/BF01309303. View

15.

Revello M, Gerna G . Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev. 2002; 15(4):680-715. PMC: 126858. DOI: 10.1128/CMR.15.4.680-715.2002. View

16.

Fernandez J, Rodrigues E, Tsuji M . Multifactorial protective mechanisms to limit viral replication in the lung of mice during primary murine cytomegalovirus infection. Viral Immunol. 2000; 13(3):287-95. DOI: 10.1089/08828240050144626. View

17.

Publicover J, Ramsburg E, Rose J . Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses. J Virol. 2004; 78(17):9317-24. PMC: 506945. DOI: 10.1128/JVI.78.17.9317-9324.2004. View

18.

Pass R, Duliege A, Boppana S, Sekulovich R, Percell S, Britt W . A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis. 1999; 180(4):970-5. DOI: 10.1086/315022. View

19.

Del Val M, Schlicht H, Volkmer H, Messerle M, Reddehase M, Koszinowski U . Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol. 1991; 65(7):3641-6. PMC: 241372. DOI: 10.1128/JVI.65.7.3641-3646.1991. View

20.

Adler S, Plotkin S, Gonczol E, Cadoz M, Meric C, Wang J . A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis. 1999; 180(3):843-6. DOI: 10.1086/314951. View